250 related articles for article (PubMed ID: 11713282)
1. Interleukin-6- and cyclic AMP-mediated signaling potentiates neuroendocrine differentiation of LNCaP prostate tumor cells.
Deeble PD; Murphy DJ; Parsons SJ; Cox ME
Mol Cell Biol; 2001 Dec; 21(24):8471-82. PubMed ID: 11713282
[TBL] [Abstract][Full Text] [Related]
2. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells.
Chen T; Wang LH; Farrar WL
Cancer Res; 2000 Apr; 60(8):2132-5. PubMed ID: 10786674
[TBL] [Abstract][Full Text] [Related]
3. Acquisition of neuroendocrine characteristics by prostate tumor cells is reversible: implications for prostate cancer progression.
Cox ME; Deeble PD; Lakhani S; Parsons SJ
Cancer Res; 1999 Aug; 59(15):3821-30. PubMed ID: 10447001
[TBL] [Abstract][Full Text] [Related]
4. Synergistic induction of the nicotinamide adenine dinucleotide-linked 15-hydroxyprostaglandin dehydrogenase by an androgen and interleukin-6 or forskolin in human prostate cancer cells.
Tong M; Tai HH
Endocrinology; 2004 May; 145(5):2141-7. PubMed ID: 14749354
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Erk mitogen-activated protein kinase pathway stimulates neuroendocrine differentiation in LNCaP cells independently of cell cycle withdrawal and STAT3 phosphorylation.
Kim J; Adam RM; Freeman MR
Cancer Res; 2002 Mar; 62(5):1549-54. PubMed ID: 11888934
[TBL] [Abstract][Full Text] [Related]
6. Changes in androgen receptor nongenotropic signaling correlate with transition of LNCaP cells to androgen independence.
Unni E; Sun S; Nan B; McPhaul MJ; Cheskis B; Mancini MA; Marcelli M
Cancer Res; 2004 Oct; 64(19):7156-68. PubMed ID: 15466214
[TBL] [Abstract][Full Text] [Related]
7. Involvement of cholesterol-rich lipid rafts in interleukin-6-induced neuroendocrine differentiation of LNCaP prostate cancer cells.
Kim J; Adam RM; Solomon KR; Freeman MR
Endocrinology; 2004 Feb; 145(2):613-9. PubMed ID: 14563701
[TBL] [Abstract][Full Text] [Related]
8. Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer.
Zerbini LF; Wang Y; Cho JY; Libermann TA
Cancer Res; 2003 May; 63(9):2206-15. PubMed ID: 12727841
[TBL] [Abstract][Full Text] [Related]
9. Activation of the androgen receptor N-terminal domain by interleukin-6 via MAPK and STAT3 signal transduction pathways.
Ueda T; Bruchovsky N; Sadar MD
J Biol Chem; 2002 Mar; 277(9):7076-85. PubMed ID: 11751884
[TBL] [Abstract][Full Text] [Related]
10. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells.
Lee SO; Lou W; Hou M; de Miguel F; Gerber L; Gao AC
Clin Cancer Res; 2003 Jan; 9(1):370-6. PubMed ID: 12538490
[TBL] [Abstract][Full Text] [Related]
11. Activated 3',5'-cyclic AMP-dependent protein kinase is sufficient to induce neuroendocrine-like differentiation of the LNCaP prostate tumor cell line.
Cox ME; Deeble PD; Bissonette EA; Parsons SJ
J Biol Chem; 2000 May; 275(18):13812-8. PubMed ID: 10788503
[TBL] [Abstract][Full Text] [Related]
12. Epidermal growth factor (EGF) receptor blockade inhibits the action of EGF, insulin-like growth factor I, and a protein kinase A activator on the mitogen-activated protein kinase pathway in prostate cancer cell lines.
Putz T; Culig Z; Eder IE; Nessler-Menardi C; Bartsch G; Grunicke H; Uberall F; Klocker H
Cancer Res; 1999 Jan; 59(1):227-33. PubMed ID: 9892211
[TBL] [Abstract][Full Text] [Related]
13. Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts.
Chen C; Koh AJ; Datta NS; Zhang J; Keller ET; Xiao G; Franceschi RT; D'Silva NJ; McCauley LK
J Biol Chem; 2004 Jul; 279(28):29121-9. PubMed ID: 15128746
[TBL] [Abstract][Full Text] [Related]
14. C/EBPdelta is a downstream mediator of IL-6 induced growth inhibition of prostate cancer cells.
Sanford DC; DeWille JW
Prostate; 2005 May; 63(2):143-54. PubMed ID: 15486993
[TBL] [Abstract][Full Text] [Related]
15. Regulation of interleukin-6-mediated PI3K activation and neuroendocrine differentiation by androgen signaling in prostate cancer LNCaP cells.
Xie S; Lin HK; Ni J; Yang L; Wang L; di Sant'Agnese PA; Chang C
Prostate; 2004 Jun; 60(1):61-7. PubMed ID: 15129430
[TBL] [Abstract][Full Text] [Related]
16. Receptor protein tyrosine phosphatase alpha signaling is involved in androgen depletion-induced neuroendocrine differentiation of androgen-sensitive LNCaP human prostate cancer cells.
Zhang XQ; Kondrikov D; Yuan TC; Lin FF; Hansen J; Lin MF
Oncogene; 2003 Oct; 22(43):6704-16. PubMed ID: 14555984
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide induces neuroendocrine differentiation in the LNCaP prostate cancer cell line through PKA, ERK, and PI3K.
Gutiérrez-Cañas I; Juarranz MG; Collado B; Rodríguez-Henche N; Chiloeches A; Prieto JC; Carmena MJ
Prostate; 2005 Apr; 63(1):44-55. PubMed ID: 15468165
[TBL] [Abstract][Full Text] [Related]
18. Elevation of cyclic adenosine 3',5'-monophosphate potentiates activation of mitogen-activated protein kinase by growth factors in LNCaP prostate cancer cells.
Chen T; Cho RW; Stork PJ; Weber MJ
Cancer Res; 1999 Jan; 59(1):213-8. PubMed ID: 9892209
[TBL] [Abstract][Full Text] [Related]
19. Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway.
Steiner H; Godoy-Tundidor S; Rogatsch H; Berger AP; Fuchs D; Comuzzi B; Bartsch G; Hobisch A; Culig Z
Am J Pathol; 2003 Feb; 162(2):655-63. PubMed ID: 12547723
[TBL] [Abstract][Full Text] [Related]
20. cAMP-induced astrocytic differentiation of C6 glioma cells is mediated by autocrine interleukin-6.
Takanaga H; Yoshitake T; Hara S; Yamasaki C; Kunimoto M
J Biol Chem; 2004 Apr; 279(15):15441-7. PubMed ID: 14754894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
